Open Access

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes

  • Michael K Wong1Email author,
  • Howard L Kaufman2Email author,
  • Gregory A Daniels3,
  • David F McDermott4,
  • Sandra Aung5,
  • James N Lowder5 and
  • Michael A Morse6
Journal for ImmunoTherapy of Cancer20142:20

DOI: 10.1186/2051-1426-2-20

Received: 28 March 2014

Accepted: 23 April 2014

Published: 18 June 2014

Abstract

Cancer registries have proven valuable with respect to validating therapeutic safety and drug efficacy, uncovering real-world implementation practices, and their evolution over time. Modern cancer therapeutics are approved as single agents oftentimes compared to the least active approved standard agent in randomized trials. However, the burgeoning diversity and number of drugs introduces a complexity that quickly outstrips the knowledge provided by these pivotal trials. This gap in information is particularly relevant when survival is the primary therapeutic endpoint. In addition, the inherent complexity of the immune response will make registries a particularly important tool in expeditiously understanding solid tumor immunotherapy and patient outcomes.

Keywords

Interleukin-2 Immunotherapy Cancer Cure Metastatic Melanoma Registry Renal cell carcinoma

Background

A registry is a structured collection of observational data, records, and/or laboratory specimens that can be collected retrospectively, prospectively, or both. The specific goals of each registry vary from storing clinically qualified specimens to studying safety, patient-reported outcomes, or cost effectiveness. Registries may study the use of a particular therapy across diseases or a specific disease independent of a therapy. Unlike classic therapeutic studies, instructions regarding treatment administration are not fixed in the registry protocol and their variation is a legitimate study target. Registries may have liberal inclusion criteria but often share attributes of a formal clinical trial such as IRB approval, patient consent and site compensation for data entry. A broad cross section of participating centers spanning academic and community sites is typically included in registries.

Registries fundamentally differ from disease databases. Projects such as National Cancer Database (NCDB) and Surveillance, Epidemiology, and End Results (SEER) program are large disease-centric databases that passively collect patient demographics, death rates, and therapy history [1, 2]. A therapy-specific registry collects additional data aiming to define and change treatment paradigms and positively impact patient morbidity, quality of life, and survival. The longitudinal follow-up of a broad patient population treated in a real world setting exposes rare or late toxicities, serves as source material to help generate hypotheses about optimal sequencing or combination of therapies, permits assessment of subject outcomes, and allows for prospective testing and validation of novel ideas. Registries also have an advantage over randomized clinical trials since they continually update and permit real-time analysis to address questions as they arise. Thus, registries occupy a unique but critical position in oncology care.

Therapy-specific registries have a track record of transforming medical practice. The Center for International Bone Marrow Transplant Registry (CIBMTR) is the prototype for how a registry globally influenced the evolution of a therapy and positively impacted patient outcomes [3, 4]. Specific examples of CIBMTR’s influence include; the refinement of preparative regimens, the supportive measures necessary to maintain the patient during neutropenia, the understanding of the MHC system to match donor/recipient, refinement of immunosuppression to manage graft versus host disease, the value of transplanting in remission and the use of unrelated donors. Outcomes continued to improve and transplant use increased despite tectonic shifts in indications for BMT, and the advent of oral targeted therapy (i.e. imatinib, dasatinib) for diseases previously only treatable with transplant.

A disease-specific registry for mRCC, The International Metastatic Renal-Cell Cancer Database Consortium (IMRDC) has published a number of reports since 2009 regarding prognostic models, sequencing of agents, and conditional survival for treatment with targeted therapy agents [57]. A unique feature of mRCC therapy has been the rapid introduction of multiple agents of similar class. The IMRDC registry observed that no meaningful differences in survival are associated with any particular sequence of VEGF and mTOR targeted therapies [6], yet at least 4 randomized clinical trials have been performed demonstrating this point [811].

Clearly there are limitations to registries. Retrospective data can be biased in multiple ways including: nonconsecutive patient selection, lower performance status patients may opt out of entering the study, heterogeneous patient populations, differences in practice patterns, variations in documentation and data abstraction, and absence of adjustments for subsequent treatments which might affect overall survival. All these potential pitfalls were considered in the construction and conduct of the interleukin-2 (IL-2) registry discussed below.

Interleukin-2 immunotherapy is a high impact registry opportunity

Cancer immunotherapy, such as HD IL-2, consistently delivers durable long term, therapy-free responses. The combination and concurrent use of emergent new therapies may enhance but also potentially threaten this curative potential. There is a critical knowledge gap about how best to sequence new drugs or to incorporate them into existing therapy choices to maximize long term patient outcomes. Immune checkpoint inhibitors add another potentially curative therapy whose interaction with IL-2 and other therapies is complex. Long-term survival and toxicity data are already available for IL-2, thus providing a reference point against which to interpret the impact of new therapies in sequence or combination. Furthermore, the availability of HD IL-2 therapy is limited by the highly technical nature of its administration due to its toxicity [12, 13]. A registry is an important resource in helping establish best practices for IL-2 therapy as new agents are improved for the treatment of melanoma and renal cell carcinoma.

With these aims firmly in mind, the Pr oleukin® O bservational Registry to Evaluate the Treatment Patterns and Cl inica l Response in M alignancy (PROCLAIMSM)(http://www.proclaimregistry.com) was created in 2011, with both retrospective and prospective cohorts. PROCLAIM establishes a clinical database on patients diagnosed with advanced kidney cancer (mRCC) and melanoma (mM) who are treated with HD IL-2 [14]. Data points include: patient demographics, peri-treatment adverse events and management, other therapies, prior, during and after the IL-2. Outcomes, including long term survival will be collected. A major goal of PROCLAIM is to serve as a resource for interested investigators to generate new ideas and to answer high priority scientific and clinical questions. Presently, there are over 35 sites participating in the PROCLAIM Registry and over 900 patients enrolled. PROCLAIM has generated a number of national meeting presentations [15, 16] and recently released its second Annual Report [17]. Analyses with regards to toxicity, response rates, outcomes and optimal drug sequence are in progress. These will have significant impact on patient selection, toxicity management and most importantly, the ‘cure’ rate for these cancers.

Conclusion

Efficiently refining the role of marketed cancer therapeutics demands that investigators generate hypotheses with the greatest potential for decisive answers and ‘real-life’ clinical utility. We believe that this can only be achieved by registries, including PROCLAIM, real-time, real-use sources of structured information which supply the raw data from which testable hypotheses arise. PROCLAIM serves this critical role by providing the data from which any interested investigator could generate new questions about high dose IL-2 therapy, including those that will establish modern benchmarks for outcomes and create best practices. Structured to support a productive collaboration between industry, academia, and community practice, PROCLAIM will serve as a model for other registries in rapidly evolving areas of oncology therapeutics where there is a pressing need to integrate more established drugs with new therapeutics.

Declarations

Acknowledgements

We thank Theresa Luna and Sandy Deveze for helpful discussion of the registry process.

Authors’ Affiliations

(1)
Department of Medicine, Suite 3455, University of Southern California
(2)
Department of Surgery, Room 2007, Rutgers Cancer Center Institute of New Jersey
(3)
Moores Cancer Center, University of California San Diego
(4)
Beth Israel Hospital Deaconess Medical Center
(5)
Prometheus Laboratories Inc
(6)
Duke University Medical Center

References

  1. National Cancer Database (NCDB). [http://www.facs.org/cancer/ncdb/index.html]
  2. Surveillance, Epidemiology, and End Results (SEER). [http://seer.cancer.gov/about/factsheets/SEER_brochure.pdf]
  3. Horowitz MM: Does matched unrelated donor transplantation have the same outcome as matched sibling transplantation in unselected patients?. Best Pract Res Clin Haematol. 2012, 25: 483-486.View ArticlePubMedGoogle Scholar
  4. Center for International Bone Marrow Transplant Registry (CIBMTR). [http://www.cibmtr.org]
  5. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009, 27: 5794-5799.View ArticlePubMedGoogle Scholar
  6. Alimohamed N, Lee JL, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Tantravahi S, Kollmannsberger C, North S, Rini BI, Choueiri TK, Heng DY: A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma [abstract]. Clin Genitourin Cancer. 2013,http://dx.doi.org/10.1016/j.clgc.2013.12.003,Google Scholar
  7. Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK: Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol. 2012, 13: 927-935.View ArticlePubMedGoogle Scholar
  8. Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Neithammer A, Lu DR, Hariharan S, Motzer RJ: Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014, 32: 760-767.View ArticlePubMedGoogle Scholar
  9. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A: RECORD-1 Study group: efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008, 372: 449-456.View ArticlePubMedGoogle Scholar
  10. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011, 378: 1931-1939.View ArticlePubMedGoogle Scholar
  11. Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Pittman KB, Sabbatini R, Rha SY, Flaig TW, Page RD, Bavbek SE, Beck JT, Patel PM, Schiff E, Vaury A, Niolat J, Gogov S, Anak O, Knox J: Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol. 2013, 31: 4504-abstractView ArticleGoogle Scholar
  12. O’Sullivan CG, Madan RA, Gulley JL: Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol. 2014, 32: 1-2.View ArticleGoogle Scholar
  13. Schwartzentruber DJ: Guidelines for the safe administration of high-dose interleukin-2. J Immunother. 2001, 24: 287-293.View ArticlePubMedGoogle Scholar
  14. Kaufman HL, Wong KK, Daniels GA, McDermott DF, Aung S, Lowder JN, Morse MA: The use of registries to improve cancer treatment: a National Database for Patients Treated with Interleukin-2 (IL-2). J Personalized Med. 2014, 4: 52-64.View ArticleGoogle Scholar
  15. Lowder JN, Aung S, Wong KK, Daniels GA, Kaufman HL, McDermott DF, Morse MA: High-dose interleukin-2 registry: PROCLAIM: Modern data on toxicities and outcomes [abstract]. J Clin Oncol. 2014, 4: 430-abstractGoogle Scholar
  16. Wong KK, Daniels GA, Kaufman HL, McDermott DF, Morse MA, Aung S, Lowder JN: High dose interleukin-2 registry, PROCLAIM, higher center-specific IL-2 dose density correlated with higher response rates [abstract]. J Immunol Ther Cancer. 2013, 1: P67-View ArticleGoogle Scholar
  17. HD IL-2 database. [http://www.proclaimregistry.com]

Copyright

© Wong et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement